Clinical Trials Directory

Trials / Active Not Recruiting

Active Not RecruitingNCT05232851

A Vaccine (PDS0101) Alone or in Combination With Pembrolizumab for the Treatment of Locally Advanced Human Papillomavirus-Associated Oropharynx Cancer

Stimulating Immune Response With Neoadjuvant Human Papilloma Virus (HPV)-16 Specific Vaccination in HPV-Oropharyngeal Squamous Cell Carcinoma (HPV-OPSCC)

Status
Active Not Recruiting
Phase
Phase 1 / Phase 2
Study type
Interventional
Enrollment
20 (actual)
Sponsor
Mayo Clinic · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

This phase I/II trial studies how well PDS0101 alone or in combination with pembrolizumab works to shrink tumor in patients with human papillomavirus-associated oropharynx cancer that has spread to nearby tissue or lymph nodes (locally advanced). PDS0101 is a vaccine made from specific peptides that may help the body build an effective immune response to kill tumor cells. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving PDS0101 with or without pembrolizumab may kill more tumor cells in patients with locally advanced human papillomavirus-associated oropharynx cancer before surgery so that it may make the tumor smaller and may reduce the amount of normal tissue that needs to be removed.

Detailed description

PRIMARY OBJECTIVE: I. To determine pathologic and human papillomavirus cell-free tumor deoxyribonucleic acid (ctHPVDNA) response to liposomal HPV-16 E6/E7 multipeptide vaccine PDS0101 (PDS0101) or PDS0101 plus pembrolizumab in patients with high risk human papillomavirus-associated oropharynx cancer (HPV-OPSCC). SECONDARY OBJECTIVES: I. To determine tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. II. To determine progression-free survival and overall survival. TERTIARY OBJECTIVES: I. To determine the safety of PDS0101 delivered alone or with pembrolizumab. CORRELATIVE RESEARCH OBJECTIVES: I. Determine the changes in tumor microenvironment (TME) with PDS0101 alone or with pembrolizumab. II. Determine circulating ctHPVDNA as a biomarker for tumor response. III. Determine HPV16-specific T-cell response utilizing multiplex flow cytometry and other parameters. OUTLINE: Patients are randomized to 1 of 2 arms. ARM A: Patients receive PDS0101 subcutaneously (SC) on day 1 of each cycle. Treatment repeats every 21 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo computed tomography (CT) or fludeoxyglucose F-18 (FDG)-positron emission tomography (PET)/CT and blood sample collection throughout the trial. Patients may undergo a biopsy during screening and on the trial. ARM B: Patients receive PDS0101 SC on day 1 and pembrolizumab intravenously (IV) over 30 minutes on day 1 of each cycle. Treatment repeats every 21 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo CT or FDG-PET/CT and blood sample collection throughout the trial. Patients may undergo a biopsy during screening and on the trial. After completion of study treatment, patients are followed every 3 months for up to 2 years.

Conditions

Interventions

TypeNameDescription
BIOLOGICALLiposomal HPV-16 E6/E7 Multipeptide Vaccine PDS0101Given SC
BIOLOGICALPembrolizumabGiven IV
PROCEDUREComputed TomographyUndergo CT, FDG-PET/CT
PROCEDUREFDG-Positron Emission TomographyUndergo FDG-PET/CT
PROCEDUREBiospecimen CollectionUndergo blood sample collection
PROCEDUREBiopsyUndergo biopsy

Timeline

Start date
2022-06-16
Primary completion
2025-04-09
Completion
2026-09-10
First posted
2022-02-10
Last updated
2026-04-14
Results posted
2026-04-14

Locations

1 site across 1 country: United States

Regulatory

Source: ClinicalTrials.gov record NCT05232851. Inclusion in this directory is not an endorsement.